Literature DB >> 23881471

Aspirin use is associated with lower prostate cancer risk in male carriers of BRCA mutations.

Matthew Cossack1, Cameron Ghaffary, Patrice Watson, Carrie Snyder, Henry Lynch.   

Abstract

Previous studies have shown that male BRCA mutation carriers stand at increased risk of developing prostate cancer and have concerns about developing cancer. Genetic counseling practitioners often discuss strategies for reducing the risk of cancer for patients at high risk due to their genetic background. Addressing modifiable health habits is one such strategy. Unfortunately, modifiable risk factors for prostate cancer have only been documented in the general population and have not yet been studied in the BRCA carrier subpopulation. Therefore, this study aimed to identify modifiable risk factors for prostate cancer in BRCA carriers. We examined prostate cancer risk factors in 74 men who were part of families with a BRCA mutation. This study examined nine dichotomous variables including: exercise, history of vasectomy, smoking history, alcohol use, finasteride use, statin use, aspirin use, coffee use, and vitamin use. The survey was sent to all cases of prostate cancer in the Hereditary Cancer Center Database at Creighton University with a known BRCA status. This study confirmed the protective benefits of daily aspirin use, which have been observed in previous studies of the general population, and suggests its benefit in BRCA carriers. Protective benefits from regular vigorous exercise and daily coffee use trended towards significance, but neither factor withstood the Bonferroni Correction for multiple comparisons.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23881471     DOI: 10.1007/s10897-013-9629-8

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  29 in total

Review 1.  Cyclooxygenases: structural, cellular, and molecular biology.

Authors:  W L Smith; D L DeWitt; R M Garavito
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

Review 2.  Unravelling the genetics of prostate cancer.

Authors:  Stephen M Edwards; Rosalind A Eeles
Journal:  Am J Med Genet C Semin Med Genet       Date:  2004-08-15       Impact factor: 3.908

3.  Comparison of next-of-kin with self-respondents regarding questions on cigarette, coffee, and alcohol consumption.

Authors:  J K McLaughlin; J S Mandel; E S Mehl; W J Blot
Journal:  Epidemiology       Date:  1990-09       Impact factor: 4.822

4.  Stigmatization and male identity: Norwegian males' experience after identification as BRCA1/2 mutation carriers.

Authors:  Nina Strømsvik; Målfrid Råheim; Nina Oyen; Lars Fredrik Engebretsen; Eva Gjengedal
Journal:  J Genet Couns       Date:  2010-03-20       Impact factor: 2.537

5.  Mendelian inheritance of familial prostate cancer.

Authors:  B S Carter; T H Beaty; G D Steinberg; B Childs; P C Walsh
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

6.  Variation in cancer risks, by mutation position, in BRCA2 mutation carriers.

Authors:  D Thompson; D Easton
Journal:  Am J Hum Genet       Date:  2001-01-19       Impact factor: 11.025

7.  Cancer Incidence in BRCA1 mutation carriers.

Authors:  Deborah Thompson; Douglas F Easton
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

Review 8.  Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement.

Authors:  Jack Cuzick; Florian Otto; John A Baron; Powel H Brown; John Burn; Peter Greenwald; Janusz Jankowski; Carlo La Vecchia; Frank Meyskens; Hans Jörg Senn; Michael Thun
Journal:  Lancet Oncol       Date:  2009-05       Impact factor: 41.316

9.  Coffee consumption and prostate cancer risk: further evidence for inverse relationship.

Authors:  Kashif Shafique; Philip McLoone; Khaver Qureshi; Hing Leung; Carole Hart; David S Morrison
Journal:  Nutr J       Date:  2012-06-13       Impact factor: 3.271

10.  BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.

Authors:  Z Kote-Jarai; D Leongamornlert; E Saunders; M Tymrakiewicz; E Castro; N Mahmud; M Guy; S Edwards; L O'Brien; E Sawyer; A Hall; R Wilkinson; T Dadaev; C Goh; D Easton; D Goldgar; R Eeles
Journal:  Br J Cancer       Date:  2011-09-27       Impact factor: 7.640

View more
  6 in total

1.  The Association Between Vasectomy and Prostate Cancer: A Systematic Review and Meta-analysis.

Authors:  Bimal Bhindi; Christopher J D Wallis; Madhur Nayan; Ann M Farrell; Landon W Trost; Robert J Hamilton; Girish S Kulkarni; Antonio Finelli; Neil E Fleshner; Stephen A Boorjian; R Jeffrey Karnes
Journal:  JAMA Intern Med       Date:  2017-09-01       Impact factor: 21.873

Review 2.  The strategies to control prostate cancer by chemoprevention approaches.

Authors:  Harold Ting; Gagan Deep; Chapla Agarwal; Rajesh Agarwal
Journal:  Mutat Res       Date:  2014-01-02       Impact factor: 2.433

Review 3.  Cysteinyl leukotrienes and their receptors: bridging inflammation and colorectal cancer.

Authors:  Sayeh Savari; Katyayni Vinnakota; Yuan Zhang; Anita Sjölander
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

Review 4.  Association between vasectomy and risk of prostate cancer: a meta-analysis.

Authors:  Yawei Xu; Lei Li; Wuping Yang; Kenan Zhang; Kaifang Ma; Haibiao Xie; Jingcheng Zhou; Lin Cai; Yanqing Gong; Zheng Zhang; Kan Gong
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-04-29       Impact factor: 5.455

5.  Live imaging and gene expression analysis in zebrafish identifies a link between neutrophils and epithelial to mesenchymal transition.

Authors:  Christina M Freisinger; Anna Huttenlocher
Journal:  PLoS One       Date:  2014-11-05       Impact factor: 3.240

6.  PCaLiStDB: a lifestyle database for precision prevention of prostate cancer.

Authors:  Yalan Chen; Xingyun Liu; Yijun Yu; Chunjiang Yu; Lan Yang; Yuxin Lin; Ting Xi; Ziyun Ye; Zhe Feng; Bairong Shen
Journal:  Database (Oxford)       Date:  2020-01-01       Impact factor: 3.451

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.